Molecular Partners AG
MOLN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 0.01 | -0.01 | 0.47 |
| FCF Yield | -40.87% | -51.94% | 59.60% | -17.02% |
| EV / EBITDA | -1.65 | -0.87 | 0.95 | -7.85 |
| Quality | ||||
| ROIC | -41.10% | -33.01% | 47.36% | -49.94% |
| Gross Margin | -855.81% | -579.80% | 73.23% | -497.19% |
| Cash Conversion Ratio | 1.10 | 0.95 | 1.01 | 1.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -70.29% | -8.97% | 172.73% | -22.93% |
| Free Cash Flow Growth | -0.26% | -151.06% | 226.98% | -200.85% |
| Safety | ||||
| Net Debt / EBITDA | 1.19 | 1.07 | -0.70 | 1.08 |
| Interest Coverage | -2,448.68 | -1,247.10 | 179.92 | -104.28 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 27,859,000.00 |
| Cash Conversion Cycle | 15.79 | 87.37 | -3.90 | 974.58 |